Theile, S.; Johansen, J.S.; Nielsen, D.L.; Jensen, B.V.; Hansen, C.P.; Hasselby, J.P.; EirÃksson, S.V.; Chen, I.M.
A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). Pharmaceutics 2022, 14, 509.
https://doi.org/10.3390/pharmaceutics14030509
AMA Style
Theile S, Johansen JS, Nielsen DL, Jensen BV, Hansen CP, Hasselby JP, EirÃksson SV, Chen IM.
A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). Pharmaceutics. 2022; 14(3):509.
https://doi.org/10.3390/pharmaceutics14030509
Chicago/Turabian Style
Theile, Susann, Julia Sidenius Johansen, Dorte Lisbet Nielsen, Benny Vittrup Jensen, Carsten Palnæs Hansen, Jane Preuss Hasselby, Sverrir VÃdalÃn EirÃksson, and Inna Markovna Chen.
2022. "A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)" Pharmaceutics 14, no. 3: 509.
https://doi.org/10.3390/pharmaceutics14030509
APA Style
Theile, S., Johansen, J. S., Nielsen, D. L., Jensen, B. V., Hansen, C. P., Hasselby, J. P., EirÃksson, S. V., & Chen, I. M.
(2022). A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC). Pharmaceutics, 14(3), 509.
https://doi.org/10.3390/pharmaceutics14030509
